Valuation: CEL-SCI Corporation

Market Cap 26.21M 22.71M 21.43M 19.44M 36.47M 2.51B 36.74M 256M 98.62M 1.27B 98.43M 96.26M 4.05B P/E 2026 *
-0.49x
P/E 2027 * -0.23x
Enterprise Value 20.65M 17.9M 16.89M 15.32M 28.74M 1.98B 28.95M 202M 77.72M 1B 77.57M 75.86M 3.19B EV / Sales 2026 *
-
EV / Sales 2027 * 3.49x
Free-Float
93.16%
Yield 2026 *
-
Yield 2027 * -
1 day+4.70%
1 week-5.76%
Current month-4.02%
1 month+0.97%
3 months+53.95%
6 months-55.95%
Current year-70.44%
1 week 1.46
Extreme 1.46
1.76
1 month 1.34
Extreme 1.34
1.76
Current year 0.89
Extreme 0.89
6.75
1 year 0.89
Extreme 0.89
10.83
3 years 0.89
Extreme 0.89
96.91
5 years 0.89
Extreme 0.89
387.04
10 years 0.89
Extreme 0.89
1,227.42
Manager TitleAgeSince
Chief Executive Officer 67 01/01/1995
Director of Finance/CFO 75 13/11/2024
Chief Tech/Sci/R&D Officer - 01/05/2024
Director TitleAgeSince
Director/Board Member 67 01/01/1995
Director/Board Member 73 22/06/2015
Chairman 69 08/07/2024
Date Insider Type Main position Quantity % Market Cap. Importance
25/8/26 Buy

Chief Executive Officer

100,000 0.5722%
14/8/26 Free

Chief Financial Officer

225,000 1.2874%
14/8/26 Free

Director

110,000 0.6294%
Change 5-day change 1-year change 3-year change Capi.($)
+4.70%-5.76%-84.25%-95.82% 26.21M
+5.04%+3.27%+50.62%+105.43% 66.93B
+1.64%-0.18%+36.02%+76.81% 61.97B
-3.12%+0.57%-12.25%+370.96% 28.26B
+4.55%-0.08%+34.70%+17.28% 24.59B
+2.86%+1.20%+2.00%-12.27% 24.3B
+1.15%-1.17%+18.94%-21.92% 19.41B
-7.03%-9.16%+161.91%+303.00% 16.77B
+3.44%-1.68%-5.00%+541.17% 14.18B
+6.15%+7.49%-1.93%+872.51% 14B
Average +1.94%-4.41%+20.08%+215.72% 27.04B
Weighted average by Cap. +2.11%-2.84%+33.87%+173.68%

Financials

2026 *2027 *
Net sales - 5.97M 5.17M 4.88M 4.43M 8.31M 572M 8.37M 58.32M 22.47M 290M 22.43M 21.94M 923M
Net income -25.08M -21.74M -20.51M -18.61M -34.91M -2.4B -35.16M -245M -94.4M -1.22B -94.21M -92.14M -3.88B -29.51M -25.57M -24.13M -21.89M -41.07M -2.83B -41.37M -288M -111M -1.44B -111M -108M -4.56B
Net Debt -5.55M -4.81M -4.54M -4.12M -7.73M -532M -7.79M -54.24M -20.9M -270M -20.86M -20.4M -859M -5.34M -4.63M -4.37M -3.96M -7.43M -512M -7.48M -52.14M -20.09M -260M -20.05M -19.61M -825M
Logo CEL-SCI Corporation
CEL-SCI Corporation is a late clinical-stage biotechnology company. It is engaged in research and development directed at improving the treatment of cancer and other diseases by using the immune system, the body’s natural defense system. It is focused on the development of product candidates and technologies, including Multikine and Ligand Epitope Antigen Presentation System technology (LEAPS). Multikine (Leukocyte Interleukin, Injection), a true first-line cancer therapy, which is designed to help the immune system target the tumor at a time when the immune system is still relatively intact and thereby thought to be better able to mount an attack on the tumor. LEAPS is designed to stimulate the human immune system to more effectively fight bacterial, viral and parasitic infections as well as autoimmune conditions, allergies, transplantation rejection and cancer, when it cannot do so on its own. The LEAPS candidates include CEL-2000, CEL-4000 and DerG-PG275(Cit) (aka, CEL-5000).
Employees
44
Date Price Change Volume
15/09/26 USD 1.555 +4.36% 49,640
11/09/26 USD 1.490 -1.97% 98,521
10/09/26 USD 1.520 -1.30% 75,964
09/09/26 USD 1.540 -6.67% 85,822
08/09/26 USD 1.650 +1.23% 283,876
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
2
Last Close Price
1.490USD
Average target price
12.50USD
Spread / Average Target
+738.93%

Annual profits - Rate of surprise

40% Discount: Identify Tomorrow's Best Investments With The Best Subscriber-Only Tools!
d
:
:
SEIZE THE OFFER!